ArticleCureus2025
Evaluation of Cardiac Function in a Patient With Hypertrophic Cardiomyopathy Before and During Pregnancy to Predict Its Outcome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk of maternal and neonatal mortality in pregnant women with hypertrophic cardiomyopathy (HCM) is considered low, and prognostic methods have not yet been established. In this study, we evaluated several pregnancies in the same patient. In each case, we were able to assess the severity of the mother's cardiac disease and estimate the prognosis. By reviewing the severity of the disease over time and its actual course, we verified the kind of assessment that is important for predicting prognosis. We present the case of a patient who was diagnosed with HCM at 18 years of age and had her first spontaneous pregnancy at 25 years of age. The baby was born at 38 weeks and was healthy, but the mother's HCM worsened after the second trimester of pregnancy, and treatment in the intensive care unit was needed after delivery. After an implantable cardioverter-defibrillator (ICD) implantation, a second pregnancy was established. However, due to repeated arrhythmias requiring ICD activation, a termination of pregnancy was performed due to the risk of worsening maternal heart failure. After radical septal myectomy, a third pregnancy was achieved. In this case, the left ventricular outflow tract stenosis disappeared, the left ventricular outflow tract pressure gradient decreased, and the pregnancy progressed well with no maternal complications. The New York Heart Association (NYHA) and modified World Health Organization (WHO) scores before conceiving were not sufficient to predict pregnancy outcomes. Changes in the disease status during pregnancy were generally consistent with the Zwangerschap bij Aangeboren HARtAfwijkingen (ZAHARA) or pregnancy and congenital heart disease score, Cardiac Disease in Pregnancy Study II (CARPREG II) score, and modified WHO classification ratings, suggesting that they are suitable for assessing risk during pregnancy, and before and after delivery in patients with HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.